A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

2025.08.15
On July 10–11, 2025, Professor Steven Campbell, Chair of Urology at West Virginia University, visited the Sun Yat-sen University Cancer Center (SYSUCC) for a two-day academic exchange. His visit brought an international, cutting-edge perspective to SYSUCC’s Department of Urology while also showcasing the department’s achievements to peers worldwide.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

2025.08.14
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.
ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT

ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT

2025.08.05
At the 2025 ASCO Annual Meeting, the West German Study Group (WSG) presented a pooled analysis (Abstract No. 502) of three trials—including the ADAPT TP study—exploring survival outcomes following chemotherapy de-escalation in HER2-positive early breast cancer (eBC). Oncology Frontier invited Prof. Jia Wang and Dr. Jinze Yu from the Second Affiliated Hospital of Dalian Medical University to interpret and comment on the findings for our readers.
BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead

BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead

2025.08.04
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China's oncology journey. Over the past decade, the field has witnessed robust growth, and BOC/BOA has emerged as a vital academic bridge linking global innovations with local practice. This year’s conference will bring together leading experts from around the world to review the remarkable achievements of the past ten years and explore future directions in cancer care.
Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

2025.07.30
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The event brought together top experts from China and abroad to discuss key issues in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics spanned basic research, innovative drug development, precision medicine, and clinical translation. At the congress, Professor Minghui Duan from Peking Union Medical College Hospital delivered a compelling presentation titled “Key Considerations and Value of Genetic Testing in Hematologic Malignancies.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Duan elaborated on the critical role and latest advances of genetic testing in the diagnosis and treatment of blood cancers, offering valuable guidance for clinical practice.
Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

2025.07.21
The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.